Multimodal Imaging in Mouse Models of Alzheimer's Disease
Hosted By: Therapeutic Laser Applications Technical Group
17 August 2022, 23:00 - 12:00
- Eastern Daylight Time (UTC - 04:00)
The advances in neuroimaging in the last decades have bridged the translational gap and enabled our understanding of the brain under different physiological and disease conditions. In animal models of Alzheimer’s disease, multiscale and multimodal imaging (e.g., positron emission tomography, magnetic resonance imaging, and optical imaging) have enabled non-invasive visualization of the neuropathology (amyloid-beta and tauopathy), neurodegeneration, and functional alterations. We recently developed novel optoacoustic tomography (resolution 100 um) and fluorescence microscopy (resolution 6 um) imaging methods that enable whole-brain non-invasive transcranial detection of amyloid-beta/tau at high spatial resolution. These platforms offer new prospects for in vivo studies into Alzheimer’s disease mechanisms in animal models and longitudinal monitoring of therapeutic responses targeting amyloid-beta deposits and tau neurofibrillary tangles. Currently, we are developing imaging tools for detecting alpha-synuclein inclusions in mouse models of Parkinson’s disease.
Subject Matter Level:
- Intermediate - Assumes basic knowledge of the topic
What You Will Learn:
- Use of noninvasive, multimodal optical imaging for studying Alzheimer’s disease and Parkinson's disease in animal models
Who Should Attend:
- Scientists, researchers, and professors
- Postdoctoral fellows
- Graduate and undergraduate students
- All of the above in the fields of biomedical engineering, biophotonics, optical imaging, and neuroscience.
About the Presenter: Ruiqing Ni, The University of Zurich
Dr. Ruiqing Ni obtained her B.Sc. in Pharmacy from Fudan University, China. Dr. Ni completed a Ph.D. in Medical Sciences at Karolinska Institute, Sweden (Supervisor Prof. Agneta Nordberg) in 2015, focusing on developing amyloid PET imaging tracers. She visited the National Institute of Radiological Science in Japan under a JSPS fellowship in Japan for half a year researching the development of Tau PET imaging probes. Dr. Ni moved to ETH Zurich in 2016 as a post-doc and is currently a group leader at the University of Zurich & ETH Zurich. Her research focuses on the development of multi-modal imaging biomarkers (PET, MRI, and photoacoustic tomography) for early detection of Alzheimer’s disease pathologies.